Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Phase I/II Study of Fractionated Stereotactic Radiotherapy for Medically Inoperable Non-Small Cell Lung Cancer (NSCLC) or Metastatic Lung Tumours

The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2012 by AHS Cancer Control Alberta.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
AHS Cancer Control Alberta
ClinicalTrials.gov Identifier:
NCT00351962
First received: July 11, 2006
Last updated: January 18, 2012
Last verified: January 2012

July 11, 2006
January 18, 2012
September 2006
Not Provided
Dose-limiting toxicity as defined by CTCAE V3 grade 4 or 5.
Same as current
Complete list of historical versions of study NCT00351962 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Phase I/II Study of Fractionated Stereotactic Radiotherapy for Medically Inoperable Non-Small Cell Lung Cancer (NSCLC) or Metastatic Lung Tumours
Phase I/II Study of Fractionated Stereotactic Radiotherapy for Medically Inoperable Non-Small Cell Lung Cancer (NSCLC) or Metastatic Lung Tumours

Medically inoperable lung cancer or metastatic lung tumours will be treated with fractionated stereotactic radiation using a schedule of 1) 12 Gy x 4 treatments or 2) 6 Gy x 10 treatments.

Not Provided
Interventional
Phase 1
Phase 2
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Lung Neoplasms
  • Lung Cancer
Procedure: Fractionated Stereotactic Radiotherapy
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
58
Not Provided
Not Provided

Inclusion Criteria:

  • non-small cell lung cancer less than 6cm; no mediastinal or distant metastases
  • Open to Alberta,Canada Residents

Exclusion Criteria:

  • tumour size greater than 6cm; inadequate pulmonary function(ie. FEV1 less than 0.8 L), Karnofsky performance status less than 70, multiple co-morbid conditions
Both
18 Years and older
No
Contact: Harold P Lau, MD 403-521-3012
Canada
 
NCT00351962
20131
Not Provided
Not Provided
AHS Cancer Control Alberta
Not Provided
Principal Investigator: Harold P Lau, MD Tom Baker Cancer Center
AHS Cancer Control Alberta
January 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP